Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Change in Accured Expenses (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Change in Accured Expenses for 12 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses rose 316.5% year-over-year to $1.2 million, compared with a TTM value of $2.1 million through Sep 2025, up 46.59%, and an annual FY2024 reading of $4.0 million, up 392.04% over the prior year.
  • Change in Accured Expenses was $1.2 million for Q3 2025 at Sunshine Biopharma, up from -$363693.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $2.9 million in Q4 2022 and bottomed at -$1.0 million in Q2 2023.
  • Average Change in Accured Expenses over 5 years is $335674.1, with a median of $17192.0 recorded in 2021.
  • Peak annual rise in Change in Accured Expenses hit 10263.39% in 2022, while the deepest fall reached 1367.54% in 2022.
  • Year by year, Change in Accured Expenses stood at -$28749.0 in 2021, then soared by 10263.39% to $2.9 million in 2022, then plummeted by 126.56% to -$776161.0 in 2023, then skyrocketed by 326.07% to $1.8 million in 2024, then plummeted by 30.2% to $1.2 million in 2025.
  • Business Quant data shows Change in Accured Expenses for SBFM at $1.2 million in Q3 2025, -$363693.0 in Q2 2025, and -$486009.0 in Q1 2025.